Straits Times Index
3,367.90 +29.33 (+0.88%) S&P 500
5,509.01 +33.92 (+0.62%) Dow
39,331.85 +162.33 (+0.41%) Nasdaq
18,028.76 +149.46 (+0.84%) Bitcoin USD
62,172.82 -658.27 (-1.05%) CMC Crypto 200
1,336.98 -7.53 (-0.56%)
ARWR Jul 2024 25.000 call
- Simply Wall St.
The past three years for Arrowhead Pharmaceuticals (NASDAQ:ARWR) investors has not been profitable
Arrowhead Pharmaceuticals, Inc. ( NASDAQ:ARWR ) shareholders should be happy to see the share price up 13% in the last...
- Business Wire
Arrowhead Pharmaceuticals to Advance RNAi-based Plozasiran into Phase 3 CAPITAN Cardiovascular Outcomes Trial
PASADENA, Calif., June 25, 2024--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced plans to advance investigational plozasiran into a Phase 3 cardiovascular outcomes trial called CAPITAN. This comes after promising results were recently announced from multiple clinical trials in three distinct patient populations, including the pivotal Phase 3 PALISADE study in patients with genetically confirmed or clinically diagnosed familial chylomicronemia syndrome (FCS), the Phase 2 SHASTA-2 s
- Business Wire
Arrowhead Pharmaceuticals Presents Preclinical Data on New RNAi-Based Obesity Program ARO-INHBE
PASADENA, Calif., June 24, 2024--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that preclinical data on ARO-INHBE, an investigational RNAi-based medicine for the treatment of obesity and metabolic diseases, were presented at the American Diabetes Association (ADA) 84th Scientific Sessions, which were held June 21-24, in Orlando, FL, and virtually.
